**Name of Journal:** *World Journal of Gastrointestinal Pathophysiology*

**Manuscript NO:** 54035

**Manuscript Type:** OPINION REVIEW

**Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation**

Weissman S *et al*. Inflammation in IBD and ASCVD

Simcha Weissman, Preetika Sinh, Tej I Mehta, Rishi K Thaker, Abraham Derman, Caleb Heiberger, Nabeel Qureshi, Viralkumar Amrutiya, Adam Atoot, Maneesh Dave, James H Tabibian

**Simcha Weissman, Nabeel Qureshi, Viralkumar Amrutiya, Adam Atoot,** Department of Medicine, Hackensack Meridian Health Palisades Medical Center, North Bergen, NJ 07047, United States

**Preetika Sinh,** Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI 53226, United States

**TejI Mehta, Caleb Heiberger**, Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, SD 57108, United States

**Rishi K Thaker,** Department of Medicine, New York Presbyterian, Brooklyn, NY 11215, United States

**Abraham Derman,** Department of Medicine, Mount Sinai-Saint Luke’s Roosevelt, NY 10025, United States

**Maneesh Dave,** Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, CA 95817, United States

**James H Tabibian**, Division of Gastroenterology, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA 91342, United States

**James H Tabibian**, David Geffen School of Medicine at UCLA, Los Angeles, CA 90001, United States

**Author contributions:** Weissman S and Sinh P were co-first authors; Weissman S, Mehta TI, Derman A, Qureshi N, Amrutiya V and Thaker RK assisted with manuscript preparation and editing; Heiberger C assisted with creating and obtaining figures; Atoot A, Tabibian JH and Sinh P drafted and critically revised the manuscript; Tabibian JH, Dave M and Sinh P provided supervision; Weissman S is the article guarantor; all authors agree to the submission of this manuscript.

**Corresponding author:** **Preetika Sinh, MD, Assistant Professor,** Division of Gastroenterology and Hepatology, Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI 53226, United States. psinh@mcw.edu

**Received:** January 17, 2020

**Revised:** April 24, 2020

**Accepted:** June 27, 2020

**Published online:**

**Abstract**

Inflammatory bowel disease (IBD) causes systemic vascular inflammation. The increased risk of venous as well as arterial thromboembolic phenomena in IBD is well established. More recently, a relationship between IBD and atherosclerotic cardiovascular disease (ASCVD) has been postulated. Systemic inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus, have well characterized cardiac pathologies and treatments that focus on prevention of disease associated ASCVD. The impact of chronic inflammation on ASCVD in IBD remains poorly characterized. This manuscript aims to review and summarize the current literature pertaining to IBD and ASCVD with respect to pathophysiology and impact of medications in order to encourage further research that can improve understanding and help develop clinical recommendations for prevention and management of ASCVD in patients with IBD.

**Key words:** Crohn’s disease; Ulcerative colitis; Atherosclerosis; Thromboembolism; Chronic inflammation; Pathophysiology

Weissman S, Sinh P, Mehta TI, Thaker RK, Derman A, Heiberger C, Qureshi N, Amrutiya V, Atoot A, Dave M, Tabibian JH. Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation. *World J Gastrointest Pathophysiol* 2020; In press

**Core tip:** Chronic inflammation in patients with inflammatory bowel disease (IBD) leads to increased risk of atherosclerotic cardiovascular disease (ASCVD). However, the role and potential impact of IBD therapy in modifying ASCVD risk, and vice-versa, remains poorly understood. Herein, we highlight the importance of ASCVD as an extraintestinal manifestation of IBD, discuss the pathophysiology common to both diseases, and explore the role of non-traditional risk factors of ASCVD in IBD. We intend to identify avenues for further clinical and translational research that may help develop clinical recommendations for the management of ASCVD risk in patients with IBD.

**INTRODUCTION**

Inflammatory bowel disease (IBD) is a chronic, systemic, relapsing and remitting inflammatory disorder of the gut due to immune and endothelial dysfunction in genetically susceptible hosts[1]. The two main phenotypic patterns of IBD are Crohn’s disease (CD) and ulcerative colitis (UC)[2]. In addition to the primary gastrointestinal manifestations of IBD, a wide-range of extra-intestinal manifestations (EIMs) has also been reported[3,4]. One of the well-recognized EIMs of IBD is the increased risk of thromboembolic phenomena[5-7]. Several recent studies have demonstrated a two to four-fold increased risk of atherosclerotic cardiovascular disease (ASCVD) in patients with IBD as compared to the general population[8]. There is growing evidence that atherosclerosis involves dysregulation of innate and adaptive immune systems along with platelet and endothelial dysfunction. Hence, it is believed that the underlying chronic inflammatory process in patients with IBD, similar to other chronic inflammatory disorders, may drive ASCVD risk[9,10]. The goal of this manuscript is to review the association between ASCVD and IBD as well as identify avenues for further research that may help develop clinical recommendations for the management of ASCVD risk in patients with IBD.

**ASCVD AS AN EIM OF IBD**

Patients with IBD are exposed to chronic, persistent, systemic inflammation over the course of their lifespan. This predisposes them to a wide range of sequelae across multiple organ systems. The EIMs associated with IBD are traditionally classified as primary and secondary[11]. Primary EIMs include joint, orocutaneous, ophthalmological, hepatobiliary, pulmonary, and renal manifestations (Figure 1). Among these some parallel IBD disease activity (episcleritis, pyoderma gangrenosum, erythema nodosum, aphthous stomatitis, peripheral arthropathy) and others do not (uveitis, ankylosing spondylitis, primary biliary cirrhosis, alopecia areata, thyroid autoimmune disease). Secondary EIMs are complications related to IBD and include osteoporosis, anemia, cholelithiasis, nephrolithiasis, and thromboembolism (Figure 1)[10].

The relationship between IBD and venous thromboembolic phenomena has been well characterized[12-14]. Patients with IBD have a 1.7 to 5.9 times increased risk of venous thromboembolism as compared to the general population[14]. However, some inflammatory conditions of the gut, such as celiac disease, do not independently increase the risk of thromboembolism[15,16] hence, the underlying pathophysiologic mechanism of thromboembolic phenomena in IBD merits further investigation.

Labeling ASCVD as an EIM of IBD adds valuable understanding to the role of chronic inflammation in the two disease processes. Currently, we do not have enough knowledge regarding effect of decreasing IBD disease burden on ASCVD and vice versa to categorize it as primary versus secondary EIM. There are no clinical human trials and long-term prospective data to assess whether ASCVD will follow the trajectory of gut inflammation in patients with IBD. Whether there is a specific time point in vascular disease after which reversibility is unachievable needs to be evaluated. The answer to these questions will help us better place ASCVD in the subcategories of EIM related to IBD. With current knowledge it can be categorized as a secondary EIM (Figure 1).

**ASCVD AND IBD**

The incidence of ASCVD is increased in patients with IBD as reported by multiple population-based and few retrospective case control studies[17-22]. Indeed, there is a two to four-fold increased risk of myocardial infarction (MI), stroke and heart failure (HF) in patients with IBD. Data from Danish and other European cohort studies, for example have shown an association between ischemic heart disease (IHD) and IBD[17,20-22]. A Canadian study reported an increased risk of IHD (IRR 1.26; 95%CI: 1.11-1.44) and cerebrovascular accidents in patients with IBD (IRR 1.32; 95%CI: 1.05–1.66)[22]. Panhwar *et al*[8] analyzed inpatient and outpatient data from Unites States and reported a two-fold increased risk of MI in patients with IBD[8].

Some studies and meta-analyses, however, have shown conflicting data[23,24]. Several reasons may account for this; for example, large retrospective cohort studies rely on billing data that are prone to miscoding. In addition, many studies lack data on disease activity and medication use that can influence the inflammatory process and hence the ASCVD events and risk. Studies that have assessed disease activity through indirect measures like steroid use or inpatient admissions have shown a more consistent positive association between the two inflammatory processes[19,20]. A pattern that has emerged over the years shows an increased risk of ASCVD with active disease and in younger and female patients as compared to the general population[9,20]. Notably, there are data showing increased subclinical atherosclerosis in patients with IBD as assessed by modalities such as carotid femoral pulse wave velocity, carotid intimal thickening, and flow-mediated dilatation (FMD)[24,25].

The effect of ASCVD related mortality in patients with IBD is debatable[12,23,26-29]. This can be attributed to multiple factors. Some studies assess mortality over the short duration of inpatient admission that might undermine the effect of long standing chronic inflammation[23,29,30]. Given the increased overall mortality among patients with IBD, it is possible that survivorship and participation bias are obscuring the potential IBD-ASCVD relationship[16]. Some studies lack rigorous matching of the control population[30]. Prospective studies with age matched control groups evaluating the role of IBD medications may be able to better assess the relationship between IBD and ASCVD.

**NON-TRADITIONAL RISK FACTORS OF ASCVD IN PATIENTS WITH IBD**

Traditional risk factors for ASCVD are age (men > 45 years, women > 55 years), male gender, family history of coronary heart disease, obesity [body mass index (BMI) > 30], hypertension, diabetes, dyslipidemia, tobacco use, alcohol use, and chronic kidney disease. However, patients with IBD tend to have lower BMI and no significant lipid abnormality[18]. Aspects like age and gender have shown deviation from the general population. Nontraditional risk factors of arterial thromboembolism in patients with IBD merit further investigation.

***Role of inflammatory markers***

IBD is characterized by high levels of C-reactive protein and various biomarkers that are associated with ASCVD, such as oxidized-low density lipoprotein, fibrinogen, matrix metallopeptidase, nuclear factor kappa-B, and interferon-γ. These are known to cause endothelial dysfunction, platelet aggregation, and hasten the development of ASCVD[31].

In a retrospective case control study, 356 IBD and 712 matched control patients, were assessed with an average follow up time of four and a half years. An increased incidence of ASCVD in patients with IBD despite having a lower burden of traditional risk factors was reported[18]. Furthermore, some non-traditional risk factors, such as white blood cells or perhaps even chronic inflammation, may have had a more robust impact on ASCVD in patients with IBD as compared to the traditional risk factors of hypertension, obesity, and hyperlipidemia[18]. We discuss in this manuscript (pathophysiology section) the biomarkers that link the two disease processes and have the potential for further translational research.

***Increased ASCVD with disease activity***

A higher risk of venous thromboembolism during active disease is well studied[9] Even though some studies have shown contrary results regarding the relationship between ASCVD and IBD, a consistent pattern of increased incidence of MI during periods of active disease has been evident[12,23,32,33]. A Danish cohort study evaluated 20795 patients with IBD and 199978 matched controls and showed increased risk of MI, stroke, and cardiovascular death during periods of active IBD. During periods of remission, these risks were similar to controls[17]. A French cohort study assessed MI, stroke and peripheral vascular disease in patients 30 d before and after hospital admission, which was taken as a surrogate marker for IBD flare, and found an increased risk of arterial thromboembolic events suggesting the importance of ongoing inflammation and its affect beyond the length of hospital admission[20]. A recent study from Olmsted County, Minnesota, showed an increased risk of MI and HF in patients with IBD with more active and extensive disease[19].

There have been no prospective studies to assess disease activity by stool, blood or clinical markers and correlate it with ASCVD events over short-term or long-term. Most studies have used surrogate markers of inflammation like steroid use, hospitalization or escalation of therapy for disease activity[34]. Studies that measure disease activity and its duration in a prospective manner are needed to better assess the outcomes of ASCVD in patients with IBD.

***Increased ASCVD risk in female and younger patients with******IBD as compared to the general population***

Multiple studies have shown that ASCVD tends to occur in women and younger patients with IBD as compared to the general population[8,35-39]. In a meta-analysis by Sun and colleagues, data from 27 studies showed pooled relative risk for ASCVD, coronary artery disease, and MI was 1.25 (95%CI: 1.08-1.44), 1.17 (95%CI: 1.07-1.27) and 1.12 (95%CI: 1.05-1.21), respectively. An association was particularly noted in women with IBD[40]. The meta-analysis by Singh and colleagues identified an overall 19% increased risk of IHD among patients with IBD, however subgroup analysis found the risk among women with IBD to be 26% and the risk among men fell below the level of statistical significance[40]. A Danish population based study that showed an increased risk of IHD in patients with IBD (IRR 1.22, 95%CI: 1.14-1.30) noted that the risk was higher in women (IRR 1.33, 95%CI: 1.21- 1.46) and younger patients of age 15-34 years (IRR 1.37, 95%CI: 0.98-1.93)[37]. An Asian cohort study showed that the adjusted hazard ratio for acute coronary syndrome in patients with IBD, compared with controls, was highest in 20 to 39 year age group at 3.28 (95%CI: 1.73-6.22), as compared to the overall risk of 1.70 (95%CI: 1.45-1.99)[36]. Recently published study from a large United States database reported higher prevalence of IHD in patients with UC and CD as compared to non-IBD patients [UC 6.9% *vs* CD 9.0% *vs* non-IBD 4.0%, OR for UC 2.09 (2.04-2.13), and CD 2.79 (2.74–2.85)]. In this patient cohort, the prevalence of MI was highest among younger patients with IBD[8].

It has been shown that patients with other chronic inflammatory conditions, *e.g.*, psoriasis, also have evidence of ASCVD at a younger age than general population[38]. Younger CD patients have more aggressive disease with more disease burden early during their life and hence it is important to assess their risk of other pro-inflammatory conditions like atherosclerosis[35]. Investigating and identifying the factors that influence this increased risk (*e.g.*, disease duration and severity) in patients with IBD will help start early intervention with appropriate therapy and thereby decrease inflammatory burden, aimed at long-term risk modification.

**PATHOPHYSIOLOGY LINKING THE TWO DISEASES**

Atherosclerosis is the most common cause of ischemic cardiomyopathy and vascular disease. Chronic inflammation involving the innate and adaptive immune system along with endothelial and platelet dysfunction is present in both atherosclerosis and IBD.

Endothelial cells, lymphocytes, monocytes, macrophages are all involved in the pathogenesis of atherosclerosis from formation of foam cells to development of plaque[39,41-44]. Disruption of the endothelium early in the process of atherosclerosis leads to upregulation of adhesion molecules, deposition of lipoproteins in the subendothelial and recruitment of circulating monocytes from the spleen and bone marrow. Some of the adhesions molecules like VCAM1, P-selectin, and ICAM1 are notable in this pathway that lead to expression of chemokines like CCR1, CCR5 and CX3C receptor 1[45-48]. Many of these adhesions’ molecules have been implicated in the pathogenesis of IBD and as potential therapeutic drug targets. Vedolizumab is an anti-integrin molecule that prevents recruitment of white blood cells to the gut by inhibiting binding of α4β7 adhesion molecules on the monocytes to the endothelial cells and is widely used to treat CD and UC[49]. Exploring the effect of such medications on ASCVD risk in IBD patients is a potential avenue of research. Further in the process of atherosclerosis, the recruited monocytes differentiate into activated macrophages and take up the apoB containing lipoproteins leading to lipid accumulation and formation of macrophage driven foam cells that overtime lay the foundation of a necrotic lipid core[50-52]. The role of endothelial dysfunction in patients with IBD has been evaluated in a small study through nitric oxide mediated dilatation of the vessels[41]. Endothelial dysfunction as assessed by FMD has been shown to be impaired in patients with active UC[42].

In addition to the innate immune system (macrophages) and endothelial dysfunction (adhesion molecules), the adaptive immune system (T and B lymphocytes, dendritic cells) is involved in the pathogenesis of atherosclerosis. Activation of T helper 1(TH) leads to production of pro-inflammatory cytokines [interleukin (IL)-1, IL-6, tumor necrosis factor] that activate local inflammatory cascade[53]. These cytokines are also involved in the pathogenesis of IBD through activation of TH1 and TH17 cells in CD and TH2 cells in UC. The JAK and STAT pathways that act downstream of cytokine mediated lymphocyte activation are implicated in the activation of IL-6 in atherosclerosis and IBD[54]. The JAK inhibitors are being extensively explored as a therapeutic target in IBD and tofacitinib (JAK 1/3 inhibitor) is currently used for treatment of moderate to severe UC[55]. Infliximab and other anti TNF medications are known therapeutic targets in IBD[56,57].

Translational research assessing pathways and cytokines of innate and adaptive immune system and, vascular endothelial dysfunction that are common to both inflammatory processes will help identify biomarkers that can be used to assess, risk stratify and develop focused preventive and treatment modalities to reduce ASCVD risk in patients with IBD.

**ASCVD RISK MODIFICATION FROM ANTI-INFLAMMATORY MEDICATIONS**

Numerous studies have examined an overlap in treatment between IBD and heart disease, with relative success (Table 1). In a retrospective matched case–control study Ungaro *et al*[43] assessed statin use in patients with IBD. Statin use was associated with a significantly decreased risk of IBD (OR: 0.68, 95%CI: 0.64-0.72), CD (OR: 0.64, 95%CI: 0.59-0.71), and UC (OR: 0.70, 95%CI: 0.65-0.76)[43]. Two studies developed animal models of IBD by chemically inducing CD and UC and showed that captopril was implicated in reducing transforming growth factor-beta1 expression and colitis-associated fibrosis[44,58]. Clopidogrel also reduced disease activity index and colonic mucosal damage index in mice – thus providing additional link between treatment of IBD and ASCVD[58].

In addition to studies showing benefit for patients with IBD taking ASCVD medications, there have been studies assessing the role of anti-inflammatory medications for ASCVD in the general population. In a multicenter randomized control (CANTOS) trial by Ridker *et al*[59], canakinumab, a human monoclonal antibody targeted at IL-1, showed a 15% reduction in deaths from heart attacks and strokes combined. Further analysis of the CANTOS trial demonstrated that patients receiving canakinumab that achieved IL-6 levels below 1.65 ng/L had a 32% reduction in major ASCVD events, whereas those at or above 1.65 ng/L received no ASCVD-related benefits[54]. Although there was an increase in fatal infections in the treatment group resulting in no overall mortality benefit, it was clearly illustrated that treatment of inflammation independent of lipid levels resulted in fewer cardiovascular events, and IL-6 could be a potential common mechanism. In addition, a nationwide retrospective cohort study noted that for patients with IBD taking 5-aminosalicylic acid (5-ASA), the incidence of IHD was significantly less compared to those not taking 5-ASA[37]. A meta-analysis assessing anti-TNF use in IBD has given us some lead regarding medications that can influence disease activity and ASCVD in patients with IBD[60]. A multicenter prospective longitudinal study in patients with IBD evaluated arterial pulse wave velocity (a surrogate marker of subclinical atherosclerosis) and found improvement with long‐term anti–TNF therapy suggesting that reduction of inflammation can lead to improvement in endothelial dysfunction[61].

**CONCLUSION**

Clinicians should be aware of the harmful effects of chronic inflammation on the heart. ASCVD risk is increased among patients with IBD especially during period of active disease. ASCVD in patients with IBD tends to favor non-traditional risk factors like younger age and female gender. The role of inflammatory markers of IBD as risk factor for ASCVD needs further investigation. Appropriate risk stratification is important in all age groups but especially in those that are diagnosed at an early age and carry the disease burden over a long time. Early escalation of care with more aggressive anti-inflammatory therapy may have a beneficial effect on chronic inflammatory processes like ASCVD, but this needs to be evaluated. Prospective studies assessing role of IBD medications on ASCVD risk and events will help tailor therapy in patients with IBD based on mechanism of the drug and help us move towards personalized medicine.

**REFERENCES**

1 **Swanson GR**, Burgess HJ, Keshavarzian A. Sleep disturbances and inflammatory bowel disease: a potential trigger for disease flare? *Expert Rev Clin Immunol* 2011; **7**: 29-36 [PMID: 21162647 DOI: 10.1586/eci.10.83]

2 **Sandborn WJ**. Current directions in IBD therapy: what goals are feasible with biological modifiers? *Gastroenterology* 2008; **135**: 1442-1447 [PMID: 18848556 DOI: 10.1053/j.gastro.2008.09.053]

3 **Mekhjian HS**, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn's disease. *Gastroenterology* 1979; **77**: 898-906 [PMID: 381094 DOI: 10.1016/0016-5085(79)90389-5]

4 **Silverberg MS**, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol* 2005; **19 Suppl A**: 5A-36A [PMID: 16151544 DOI: 10.1155/2005/269076]

5 **Tabibian JH**, Streiff MB. Inflammatory bowel disease-associated thromboembolism: a systematic review of outcomes with anticoagulation versus catheter-directed thrombolysis. *Inflamm Bowel Dis* 2012; **18**: 161-171 [PMID: 21805543 DOI: 10.1002/ibd.21307]

6 **Tabibian JH**, Roth BE. Local thrombolysis: a newer approach to treating inflammatory bowel disease-related thromboembolism. *J Clin Gastroenterol* 2009; **43**: 391-398 [PMID: 19247203 DOI: 10.1097/MCG.0b013e31818a846e]

7 **Tabibian JH**, Lada SJ, Tabibian N. Combined inferior vena cava & renal vein thromboses: case and synopsis of thromboembolism in inflammatory bowel disease. *Medscape J Med* 2008; **10**: 6 [PMID: 18324316]

8 **Panhwar MS**, Mansoor E, Al-Kindi SG, Sinh P, Katz J, Oliveira GH, Cooper GS, Ginwalla M. Risk of Myocardial Infarction in Inflammatory Bowel Disease: A Population-based National Study. *Inflamm Bowel Dis* 2019; **25**: 1080-1087 [PMID: 30500938 DOI: 10.1093/ibd/izy354]

9 **Grainge MJ**, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. *Lancet* 2010; **375**: 657-663 [PMID: 20149425 DOI: 10.1016/S0140-6736(09)61963-2]

10 **Conti P**, Shaik-Dasthagirisaeb Y. Atherosclerosis: a chronic inflammatory disease mediated by mast cells. *Cent Eur J Immunol* 2015; **40**: 380-386 [PMID: 26648785 DOI: 10.5114/ceji.2015.54603]

11 **Garber A**, Regueiro M. Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis, and Management. *Curr Gastroenterol Rep* 2019; **21**: 31 [PMID: 31098819 DOI: 10.1007/s11894-019-0698-1]

12 **Sridhar AR**, Parasa S, Navaneethan U, Crowell MD, Olden K. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. *J Crohns Colitis* 2011; **5**: 287-294 [PMID: 21683298 DOI: 10.1016/j.crohns.2011.01.011]

13 **Saleh T**, Matta F, Yaekoub AY, Danescu S, Stein PD. Risk of venous thromboembolism with inflammatory bowel disease. *Clin Appl Thromb Hemost* 2011; **17**: 254-258 [PMID: 20211927 DOI: 10.1177/1076029609360528]

14 **Novacek G**, Weltermann A, Sobala A, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Miehsler W, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Eichinger S. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. *Gastroenterology* 2010; **139**: 779-787, 787.e1 [PMID: 20546736 DOI: 10.1053/j.gastro.2010.05.026]

15 **Tan VP**, Chung A, Yan BP, Gibson PR. Venous and arterial disease in inflammatory bowel disease. *J Gastroenterol Hepatol* 2013; **28**: 1095-1113 [PMID: 23662785 DOI: 10.1111/jgh.12260]

16 **Schicho R**, Marsche G, Storr M. Cardiovascular complications in inflammatory bowel disease. *Curr Drug Targets* 2015; **16**: 181-188 [PMID: 25642719 DOI: 10.2174/1389450116666150202161500]

17 **Kristensen SL**, Ahlehoff O, Lindhardsen J, Erichsen R, Jensen GV, Torp-Pedersen C, Nielsen OH, Gislason GH, Hansen PR. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death--a Danish nationwide cohort study. *PLoS One* 2013; **8**: e56944 [PMID: 23457642 DOI: 10.1371/journal.pone.0056944]

18 **Yarur AJ**, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. *Am J Gastroenterol* 2011; **106**: 741-747 [PMID: 21386828 DOI: 10.1038/ajg.2011.63]

19 **Aniwan S**, Pardi DS, Tremaine WJ, Loftus EV Jr. Increased Risk of Acute Myocardial Infarction and Heart Failure in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol* 2018; **16**: 1607-1615.e1 [PMID: 29702298 DOI: 10.1016/j.cgh.2018.04.031]

20 **Kirchgesner J**, Beaugerie L, Carrat F, Andersen NN, Jess T, Schwarzinger M; BERENICE study group. Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. *Gut* 2018; **67**: 1261-1268 [PMID: 28647686 DOI: 10.1136/gutjnl-2017-314015]

21 **Kappelman MD**, Horvath-Puho E, Sandler RS, Rubin DT, Ullman TA, Pedersen L, Baron JA, Sørensen HT. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. *Gut* 2011; **60**: 937-943 [PMID: 21339206 DOI: 10.1136/gut.2010.228585]

22 **Bernstein CN**, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. *Clin Gastroenterol Hepatol* 2008; **6**: 41-45 [PMID: 18063423 DOI: 10.1016/j.cgh.2007.09.016]

23 **Dorn SD**, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. *Am J Gastroenterol* 2007; **102**: 662-667 [PMID: 17156143 DOI: 10.1111/j.1572-0241.2006.01018.x]

24 **Zanoli L**, Signorelli SS, Inserra G, Castellino P. Subclinical Atherosclerosis in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. *Angiology* 2017; **68**: 463 [PMID: 27784730 DOI: 10.1177/0003319716675076]

25 **Wu GC**, Leng RX, Lu Q, Fan YG, Wang DG, Ye DQ. Subclinical Atherosclerosis in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. *Angiology* 2017; **68**: 447-461 [PMID: 27252243 DOI: 10.1177/0003319716652031]

26 **Mitchell NE**, Harrison N, Junga Z, Singla M. Heart Under Attack: Cardiac Manifestations of Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2018; **24**: 2322-2326 [PMID: 29788235 DOI: 10.1093/ibd/izy157]

27 **Osterman MT**, Yang YX, Brensinger C, Forde KA, Lichtenstein GR, Lewis JD. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. *Clin Gastroenterol Hepatol* 2011; **9**: 875-880 [PMID: 21749853 DOI: 10.1016/j.cgh.2011.06.032]

28 **Bewtra M**, Kaiser LM, TenHave T, Lewis JD. Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. *Inflamm Bowel Dis* 2013; **19**: 599-613 [PMID: 23388544 DOI: 10.1097/MIB.0b013e31827f27ae]

29 **Dave M,** Mehta K, Badheka A, Loftus E. Inflammatory Bowel Disease Does Not Impact Mortality, but Increases Length of Hospitalization in Patients with Acute Myocardial Infarction. *Am J Gastroenterol* 2013; 108 [DOI: 10.14309/00000434-201310001-01734]

30 **Barnes EL**, Beery RM, Schulman AR, McCarthy EP, Korzenik JR, Winter RW. Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database. *Inflamm Bowel Dis* 2016; **22**: 2229-2237 [PMID: 27542135 DOI: 10.1097/MIB.0000000000000899]

31 **Hansson GK**. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005; **352**: 1685-1695 [PMID: 15843671 DOI: 10.1056/NEJMra043430]

32 **Ha C**, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. *Am J Gastroenterol* 2009; **104**: 1445-1451 [PMID: 19491858 DOI: 10.1038/ajg.2009.81]

33 **Ruisi P**, Makaryus JN, Ruisi M, Makaryus AN. Inflammatory bowel disease as a risk factor for premature coronary artery disease. *J Clin Med Res* 2015; **7**: 257-261 [PMID: 25699123 DOI: 10.14740/jocmr2102w]

34 **Aarestrup J**, Jess T, Kobylecki CJ, Nordestgaard BG, Allin KH. Cardiovascular Risk Profile Among Patients With Inflammatory Bowel Disease: A Population-based Study of More Than 100 000 Individuals. *J Crohns Colitis* 2019; **13**: 319-323 [PMID: 30321330 DOI: 10.1093/ecco-jcc/jjy164]

35 **Herzog D**, Fournier N, Buehr P, Rueger V, Koller R, Heyland K, Nydegger A, Spalinger J, Schibli S, Petit LM, Braegger CP; Swiss IBD Cohort Study Group. Age at disease onset of inflammatory bowel disease is associated with later extraintestinal manifestations and complications. *Eur J Gastroenterol Hepatol* 2018; **30**: 598-607 [PMID: 29360691 DOI: 10.1097/MEG.0000000000001072]

36 **Tsai MS**, Lin CL, Chen HP, Lee PH, Sung FC, Kao CH. Long-term risk of acute coronary syndrome in patients with inflammatory bowel disease: a 13-year nationwide cohort study in an Asian population. *Inflamm Bowel Dis* 2014; **20**: 502-507 [PMID: 24412991 DOI: 10.1097/01.MIB.0000441200.10454.4f]

37 **Rungoe C**, Basit S, Ranthe MF, Wohlfahrt J, Langholz E, Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. *Gut* 2013; **62**: 689-694 [PMID: 22961677 DOI: 10.1136/gutjnl-2012-303285]

38 **Santilli S**, Kast DR, Grozdev I, Cao L, Feig RL, Golden JB, Debanne SM, Gilkeson RC, Orringer CE, McCormick TS, Ward NL, Cooper KD, Korman NJ. Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center. *J Transl Med* 2016; **14**: 217 [PMID: 27448600 DOI: 10.1186/s12967-016-0947-0]

39 **Ruparelia N**, Chai JT, Fisher EA, Choudhury RP. Inflammatory processes in cardiovascular disease: a route to targeted therapies. *Nat Rev Cardiol* 2017; **14**: 133-144 [PMID: 27905474 DOI: 10.1038/nrcardio.2016.185]

40 **Singh S**, Singh H, Loftus EV Jr, Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2014; **12**: 382-93.e1: quiz e22 [PMID: 23978350 DOI: 10.1016/j.cgh.2013.08.023]

41 **Hatoum OA**, Binion DG, Otterson MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. *Gastroenterology* 2003; **125**: 58-69 [PMID: 12851871 DOI: 10.1016/S0016-5085(03)00699-1]

42 **Principi M**, Mastrolonardo M, Scicchitano P, Gesualdo M, Sassara M, Guida P, Bucci A, Zito A, Caputo P, Albano F, Ierardi E, Di Leo A, Ciccone MM. Endothelial function and cardiovascular risk in active inflammatory bowel diseases. *J Crohns Colitis* 2013; **7**: e427-e433 [PMID: 23473915 DOI: 10.1016/j.crohns.2013.02.001]

43 **Ungaro R**, Chang HL, Côté-Daigneault J, Mehandru S, Atreja A, Colombel JF. Statins Associated With Decreased Risk of New Onset Inflammatory Bowel Disease. *Am J Gastroenterol* 2016; **111**: 1416-1423 [PMID: 27296939 DOI: 10.1038/ajg.2016.233]

44 **Wengrower D**, Zanninelli G, Pappo O, Latella G, Sestieri M, Villanova A, Faitelson Y, Pines M, Goldin E. Prevention of fibrosis in experimental colitis by captopril: the role of tgf-beta1. *Inflamm Bowel Dis* 2004; **10**: 536-545 [PMID: 15472513 DOI: 10.1097/00054725-200409000-00007]

45 **Cybulsky MI**, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. *Science* 1991; **251**: 788-791 [PMID: 1990440 DOI: 10.1126/science.1990440]

46 **Heidt T**, Sager HB, Courties G, Dutta P, Iwamoto Y, Zaltsman A, von Zur Muhlen C, Bode C, Fricchione GL, Denninger J, Lin CP, Vinegoni C, Libby P, Swirski FK, Weissleder R, Nahrendorf M. Chronic variable stress activates hematopoietic stem cells. *Nat Med* 2014; **20**: 754-758 [PMID: 24952646 DOI: 10.1038/nm.3589]

47 **Combadière C**, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A, Mallat Z. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. *Circulation* 2008; **117**: 1649-1657 [PMID: 18347211 DOI: 10.1161/CIRCULATIONAHA.107.745091]

48 **Tacke F**, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. *J Clin Invest* 2007; **117**: 185-194 [PMID: 17200718 DOI: 10.1172/JCI28549]

49 **Feagan BG**, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2013; **369**: 699-710 [PMID: 23964932 DOI: 10.1056/NEJMoa1215734]

50 **Ley K**, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. *Arterioscler Thromb Vasc Biol* 2011; **31**: 1506-1516 [PMID: 21677293 DOI: 10.1161/ATVBAHA.110.221127]

51 **Robbins CS**, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, Gorbatov R, Sukhova GK, Gerhardt LM, Smyth D, Zavitz CC, Shikatani EA, Parsons M, van Rooijen N, Lin HY, Husain M, Libby P, Nahrendorf M, Weissleder R, Swirski FK. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. *Nat Med* 2013; **19**: 1166-1172 [PMID: 23933982 DOI: 10.1038/nm.3258]

52 **Khallou-Laschet J**, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A, Caligiuri G. Macrophage plasticity in experimental atherosclerosis. *PLoS One* 2010; **5**: e8852 [PMID: 20111605 DOI: 10.1371/journal.pone.0008852]

53 **Ait-Oufella H**, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. *Arterioscler Thromb Vasc Biol* 2011; **31**: 969-979 [PMID: 21508343 DOI: 10.1161/ATVBAHA.110.207415]

54 **Ridker PM**, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, Everett BM, Glynn RJ. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). *Eur Heart J* 2018; **39**: 3499-3507 [PMID: 30165610 DOI: 10.1093/eurheartj/ehy310]

55 **Sandborn WJ**, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med* 2017; **376**: 1723-1736 [PMID: 28467869 DOI: 10.1056/NEJMoa1606910]

56 **Lichtenstein GR**, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol* 2018; **113**: 481-517 [PMID: 29610508 DOI: 10.1038/ajg.2018.27]

57 **Rubin DT**, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol* 2019; **114**: 384-413 [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152]

58 **Patel SH**, Rachchh MA, Jadav PD. Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease. *Indian J Pharmacol* 2012; **44**: 744-748 [PMID: 23248405 DOI: 10.4103/0253-7613.103278]

59 **Ridker PM**, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med* 2017; **377**: 1119-1131 [PMID: 28845751 DOI: 10.1056/NEJMoa1707914]

60 **Fumery M,** Singh AG, Khera R, Prokop L, Sandborn WJ, Curtis JR, Singh S. Biologic Therapy and Immunodulators are Associated with Decreased Risk of Cardiovascular Events in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. *Gastroenterology* 2017; 152: S77 [DOI: 10.1016/S0016-5085(17)30607-8]

61 **Zanoli L**, Ozturk K, Cappello M, Inserra G, Geraci G, Tuttolomondo A, Torres D, Pinto A, Duminuco A, Riguccio G, Aykan MB, Mulé G, Cottone S, Perna AF, Laurent S, Fatuzzo P, Castellino P, Boutouyrie P. Inflammation and Aortic Pulse Wave Velocity: A Multicenter Longitudinal Study in Patients With Inflammatory Bowel Disease. *J Am Heart Assoc* 2019; **8**: e010942 [PMID: 30712441 DOI: 10.1161/JAHA.118.010942]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflict of interests.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 17, 2020

**First decision:** April 9, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Chiba T, Yang MS **S-Editor:** Dou Y **L-Editor:** **E-Editor:**

**Figure Legends**

**Figure 1** **Illustration summarizing the primary and secondary extra-intestinal manifestations associated with inflammatory bowel disease, including atherosclerotic cardiovascular disease as a more recently recognized secondary extra-intestinal manifestation of inflammatory bowel disease.** EIM: Extra-intestinal manifestation; ASCVD: Atherosclerotic cardiovascular disease.

**Table 1** **Clinical studies that have found overlap in treatment between inflammatory bowel disease and atherosclerotic cardiovascular disease indicating that the underlying chronic inflammatory process in patients with inflammatory bowel disease may drive atherosclerotic cardiovascular disease risk, and vice versa**

|  |  |  |  |
| --- | --- | --- | --- |
| **Ref.** | **Study type** | **The number of patients** | **Efficacy in treatment overlap** |
| Ungaro *et al*[43] | Retrospective matched case-control study | A total of 9617 cases and 46665 controls were included in the analysis | Statistically significant decreased risk of new onset IBD in patients taking statin therapy |
| Wengrower *et al*[44] | Chemically induced colitis, animal model | A total of 40 male rats were divided into normal control, captopril only, induced-colitis control, and induced-colitis with captopril arms | A significant reduction in fibrosis, levels of TGF-beta1 mRNA, and protein was found in patients with IBD taking captopril |
| Patel *et al*[58] | Chemically induced Crohn’s and UC, animal model | A total of 48 mice, divided into induced Crohn’s and UC arms, further divided into normal, disease, disease with standard therapy, and disease with clopidogrel | A statistically significant reduction in disease activity and colonic mucosal damage was seen in mice on clopidogrel |
| Rungoe *et al*[37] | Nationwide, population-based retrospective cohort study | A total of 28833 patients with IBD were compared to matched non-IBD patients from a dataset of 4.6 million | A statistically significant reduction in risk of ischemic heart disease was seen in patients given 5-ASA |
| Zanoli *et al*[61] | Multicenter prospective longitudinal study | 334 patients with IBD were followed for 4 yr | In patients with IBD anti-TNFα therapy reduced aortic pulse-wave velocity (a surrogate for cardiovascular risk) |

IBD: Inflammatory bowel disease; TGF: Transforming growth factor; UC: Ulcerative colitis; 5-ASA: 5-aminosalicylic acid; TNF: Tumor necrosis factor.